Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down

While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.

Unrecognizable male scientist is plugging a microscopy app into a brain study interface. Science concept for biosciences, molecular engineering, bioengineering, pharmacogenomics, pharmacogenetics.
Biogen sees rapid progress in many aspects of CNS R&D • Source: Shutterstock

“What’s happening in neuroscience right now is like nothing we’ve seen before. Neuroscience is at an inflection point. We have seen the signs and Biogen has chosen to step forward and lead.” Michael Ehlers, Biogen Inc.’s executive vice president, R&D, is convinced that the company is in the right place at the right time, but Biogen’s attitude is unusual.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

Quotables: Pharma Leaders On The Month’s Hot Topics

 

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Soriot Cautions Europe Amid More US Expansion

 
• By 

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.